Recommendations and rationale for the treatment of pelvic inflammatory disease

被引:22
作者
Jaiyeoba, Oluwatosin [1 ]
Lazenby, Gweneth [1 ]
Soper, David E. [1 ]
机构
[1] Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA
关键词
antimicrobial treatment; pelvic inflammatory disease; PID; tubo-ovarian abscess; MYCOPLASMA-GENITALIUM; OUTPATIENT TREATMENT; TREATMENT STRATEGIES; TUBOOVARIAN ABSCESS; ACUTE SALPINGITIS; CLINICAL CURE; DOUBLE-BLIND; AZITHROMYCIN; MOXIFLOXACIN; DOXYCYCLINE;
D O I
10.1586/ERI.10.156
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pelvic inflammatory disease (PID) is one of the most common serious infections of nonpregnant women of reproductive age. Management of PID is directed at containment of infection. Goals of therapy include the resolution of clinical symptoms and signs, the eradication of pathogens from the genital tract and the prevention of sequelae including infertility, ectopic pregnancy and chronic pelvic pain. The choice of an antibiotic regimen used to treat PID relies upon the appreciation of the polymicrobial etiology of this ascending infection including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and other lower genital tract endogenous anaerobic and facultative bacteria, many of which are associated with bacterial vaginosis. Currently available evidence and the CDC treatment recommendations support the use of broad-spectrum antibiotic regimens that adequately cover the above named microorganisms. The outpatient treatment of mild-to-moderate PID should include tolerated antibiotic regimens consisting of an extended-spectrum cephalosporin in conjunction with either azithromycin or doxycycline. Clinically severe PID should prompt hospitalization and imaging to rule out a tubo ovarian abscess. Parenteral broad-spectrum antibiotic therapy with activity against a polymicrobial flora, particularly Gram-negative aerobes and anaerobes, should be implemented.
引用
收藏
页码:61 / 70
页数:10
相关论文
共 53 条
[1]  
[Anonymous], 2008, SEX TRANSM DIS SURV
[2]   Antimicrobial resistance associated with the treatment of bacterial vaginosis [J].
Beigi, RH ;
Austin, MN ;
Meyn, LA ;
Krohn, MA ;
Hillier, SL .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (04) :1124-1129
[3]   Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease [J].
Bevan, CD ;
Ridgway, GL ;
Rothermel, CD .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2003, 31 (01) :45-54
[4]   Persistence of Mycoplasma genitalium Following Azithromycin Therapy [J].
Bradshaw, Catriona S. ;
Chen, Marcus Y. ;
Fairley, Christopher K. .
PLOS ONE, 2008, 3 (11)
[5]   Azithromycin failure in Mycoplasma genitalium urethritis [J].
Bradshaw, CS ;
Jensen, JS ;
Tabrizi, SN ;
Read, TRH ;
Garland, SM ;
Hopkins, CA ;
Moss, LM ;
Fairley, CK .
EMERGING INFECTIOUS DISEASES, 2006, 12 (07) :1149-1152
[6]  
*CDCP, 2007, UPD TREATM REC GON I
[7]  
*CDCP, 2006, MMWR-MORBID MORTAL W, V55, P56
[8]   Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis [J].
Cohen, CR ;
Mugo, NR ;
Astete, SG ;
Odondo, R ;
Manhart, LE ;
Kiehlbauch, JA ;
Stamm, WE ;
Waiyaki, PG ;
Totten, PA .
SEXUALLY TRANSMITTED INFECTIONS, 2005, 81 (06) :463-466
[9]   EFFICACY OF SINGLE-AGENT THERAPY FOR THE TREATMENT OF ACUTE PELVIC INFLAMMATORY DISEASE WITH CIPROFLOXACIN [J].
CROMBLEHOLME, WR ;
SCHACHTER, J ;
OHMSMITH, M ;
WHIDDEN, R ;
SWEET, RL .
AMERICAN JOURNAL OF MEDICINE, 1989, 87 (5A) :S142-S147
[10]  
del Rio C., 2007, Morbidity and Mortality Weekly Report, V56, P332